Kyle Deans
Papers
1
Total Citations
7
H-Index
1
About
Kyle Deans is a translational researcher at the forefront of personalized oncology, with a primary focus on thoracic surgical oncology and precision medicine. His most significant contribution to date is leading the first-in-human intrathoracic implantation of multidrug-eluting microdevices for *in situ* chemotherapeutic sensitivity testing in non-small cell lung cancer (NSCLC). This groundbreaking proof-of-concept study, published in 2022, demonstrated the safety and feasibility of implanting and retrieving a novel microdevice during operative resection. By enabling real-time, patient-specific drug response profiling directly within the tumor microenvironment, Deans’ work addresses a critical gap in adjuvant therapy, where the inability to predict optimal treatment often limits patient outcomes. This innovative approach has the potential to revolutionize how clinicians select chemotherapy regimens, moving beyond one-size-fits-all protocols. With 7 citations already, this seminal paper is rapidly gaining traction in the surgical oncology community. Deans’ research bridges the gap between engineering and clinical practice, positioning him as a rising leader in the quest for truly individualized cancer care.
Research Focus
Key Achievements
Top Papers
- 1